Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on August 11, 2025. The filing serves to announce the issuance of a press release containing financial information for the fiscal quarter ended June 30, 2025.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the financial details are contained within the attached press release (Exhibit 99.1) and are not included in the body of this Form 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document functions solely as a notification of the press release's existence.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, nor will it be incorporated by reference into any other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures for the quarter ended June 30, 2025.
- Verify the company's status as an emerging growth company and its implications for financial reporting.
- Confirm the trading symbol (CVKD) and exchange (Nasdaq Capital Market) for current market data.
- Note that the financial data in the press release is not legally "filed" with the SEC and carries different liability standards.